Bio-Rad Laboratories Inc. Class A
Find Ratings ReportsBIO-RAD LABORATORIES INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its subsector. BIO-RAD LABORATORIES INC is extremely liquid. Currently, the Quick Ratio is 4.04 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 9.09% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 681.18 | 730.29 |
EBITDA ($mil) | 136.77 | 156.48 |
EBIT ($mil) | 99.54 | 120.97 |
Net Income ($mil) | 349.71 | 827.73 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 1612.85 | 1796.25 |
Total Assets ($mil) | 12299.07 | 13501.67 |
Total Debt ($mil) | 1405.4 | 1388.11 |
Equity ($mil) | 8741.13 | 9615.25 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 59.06 | 58.97 |
EBITDA Margin | 20.07 | 21.42 |
Operating Margin | 14.61 | 16.56 |
Sales Turnover | 0.22 | 0.21 |
Return on Assets | -5.18 | -26.86 |
Return on Equity | -7.29 | -37.73 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 5.83 | 5.55 |
Debt/Capital | 0.14 | 0.13 |
Interest Expense | 12.36 | 11.68 |
Interest Coverage | 8.05 | 10.35 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 28.52 | 29.6 |
Div / share | 0.0 | 0.0 |
EPS | 12.14 | 27.78 |
Book value / share | 306.5 | 324.88 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 214040.0 | 269424.0 |
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.08 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 23.59. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, BIO-RAD LABORATORIES INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIO NM | Peers 53.34 | BIO 25.28 | Peers 44.47 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. BIO's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BIO is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
BIO 27.04 | Peers 26.06 | BIO NA | Peers 1.95 | |||||||||||||||||||||
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. BIO is trading at a premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
BIO 1.08 | Peers 23.59 | BIO 82.28 | Peers 123.02 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BIO is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, BIO is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
BIO 3.55 | Peers 14.13 | BIO -4.68 | Peers 27.20 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BIO is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. BIO significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||